FOLR1 and ovarian carcinoma: This phase I expansion cohort study examined the safety and clinical effectiveness of mirvetuximab soravtansine in forty‐six heavily pre‐treated patients with FRα‐positive and platinum‐resistant ovarian cancer (NCT01609556).257